Clinical Research
person

Roisin C.

Country
Ireland
Department
Cardiology

Research Overview

assignment
1
Clinical Trials ·
location_city
1
Research Sites

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 310 partner sites.

Specializations

Prostate Cancer Therapeutics

Focused on advanced and high‑risk Prostate Cancer strategies, including hormonal manipulation and targeted radiation approaches.

  • Androgen Deprivation Therapy
  • Darolutamide
  • Metastatic Castration‑Resistant Prostate Cancer
  • Functional Imaging‑Guided Oligometastatic Treatment

Efforts aim to improve survival outcomes while preserving quality of life for men with aggressive disease.

Breast Cancer Hormone‑Responsive Treatments

Engaged in clinical studies of endocrine‑based regimens for Hormone Receptor‑Positive, HER2‑Negative Breast Cancer, spanning early and high‑risk settings.

  • CDK4/6 Inhibitors
  • Selective Estrogen Receptor Degraders
  • Oncotype DX Recurrence Score
  • Adjuvant Chemotherapy Decision‑Making

Research seeks to refine adjuvant therapy selection and reduce overtreatment.

Lung Cancer Targeted and Immunotherapy

Investigates novel combinations for Non‑Small Cell Lung Cancer, with emphasis on molecular subtypes and immune modulation.

  • KRAS G12C Inhibition
  • Pembrolizumab‑Based Immunotherapy
  • Axitinib Combination Strategies
  • c‑Met Positive Tumors

Goal is to extend progression‑free intervals and enhance overall survival.

Cardiovascular Disease and Heart Failure Management

Contributes to trials addressing Heart Failure with Preserved Ejection Fraction and systemic inflammation, as well as lipid‑related risk reduction.

  • Ziltivekimab
  • Lipoprotein(a) Lowering Therapies
  • Inflammatory Biomarker‑Targeted Interventions
  • Cardiovascular Event Prevention

Studies aim to lower cardiovascular mortality and hospitalization rates.

Renal Cell Carcinoma and Emerging Oncology

Participates in investigations of immune‑checkpoint and VEGF pathway blockade for Renal Cell Carcinoma and related malignancies.

  • Pembrolizumab
  • Axitinib
  • Combination Immunotherapy Regimens
  • Biomarker‑Driven Patient Selection

Efforts focus on optimizing therapeutic sequencing and durability of response.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.